Short answer
Bio-Techne (TECH) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers). Merck KGaA agreed to acquire Bio-Techne for $73.00 cash per share, converting the company into a wholly owned subsidiary.
Bio-Techne 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Merck KGaA agreed to acquire Bio-Techne for $73.00 cash per share, converting the company into a wholly owned subsidiary
- Shareholder approval and antitrust or investment-screening clearances remain key closing conditions
- Expected closing deadline March 25, 2027, with extensions to September 25, 2027 for unresolved regulatory approvals
- Bio-Techne termination fee $230,455,000; Merck termination fee $576,140,000, materially shaping deal-break risk
- No-shop provisions limit competing bids, though the board can consider a superior proposal subject to conditions and the termination fee
Item 5.02 · Departure/Election of Directors or Officers
- Filing references February 11, 2026 Form 8-K for officer, director, and compensation details
- Changes in insider holdings reflected through SEC Forms 3 or 4
- Proxy materials expected to disclose transaction participants and their interests
- Shane V. Bohnen signed as Senior Vice President, General Counsel and Secretary on June 25, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-Techne 8-K filings
Get the next TECH 8-K as it lands
Follow TECH for push alerts, or ask the research agent what this filing means.